Not only does this show Pfizer has huge cash reserves and the ability to pay a fair price for RAP. The offer is a 78% premium on Biohaven's closing share price, while the RAP offer is only a 27.8% premium on the share price. Vote NO!
- Forums
- ASX - By Stock
- RAP
- Valuing ResApp Health
Valuing ResApp Health, page-40
- There are more pages in this discussion • 427 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)